<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872780</url>
  </required_header>
  <id_info>
    <org_study_id>08-101</org_study_id>
    <nct_id>NCT01872780</nct_id>
  </id_info>
  <brief_title>Identification of Null Allelic Variant of CYP2C8 In A Korean Population</brief_title>
  <official_title>The Effect of CYP2C8 E274Q, a Novel 23452 G&gt;T SNP, on the Disposition of Rosiglitazone in Healthy Subjects: The Genetic Polymorphisms of CYP2C8 in a Korean Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The genotype profile of CYP2C8 was analyzed in a Korean population. Frequency in multi-ethnic
      population and in vivo functionality of novel null allelic CYP2C8 variant were evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whole blood samples from 50 unrelated Korean subjects were genotyped for 3kb of 5' upstream
      region, all exon-intron boundaries, exons, and UTR regions of CYP2C8 gene by direct
      sequencing. Genotyping of CYP2C8 has been addressed only for null allelic variant, CYP2C8*11
      using pyrosequencing in the 447 Koreans, 93 African-Americans, 100 Caucasians, 348 Chineses
      and 100 Vietnameses. Then, in-vivo single PK study of CYP2C8 probe, rosiglitazone(4mg), was
      conducted in 7 healthy subjects with CYP2C8*1/*1 and 2 with CY2C8*1/*11.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>12hr</time_frame>
    <description>0h,0.33h,0.66h,1h,1.5h,2h,3h,4h,6h,8h,12h,24h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>12hr</time_frame>
    <description>0h,0.33h,0.66h,1h,1.5h,2h,3h,4h,6h,8h,12h,24h</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>avandia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>genetic polymorphism</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>avandia CYP2C8 genotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>single oral administration of 4mg of rosiglitazone</description>
    <arm_group_label>rosiglitazone</arm_group_label>
    <arm_group_label>genetic polymorphism</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>CYP2C8 genotype</intervention_name>
    <description>CYP2C8*11.</description>
    <arm_group_label>rosiglitazone</arm_group_label>
    <arm_group_label>genetic polymorphism</arm_group_label>
    <other_name>avandia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer

        Exclusion Criteria:

          -  Medical problems in taking probe drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Gook Shin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Jae-Gook Shin</investigator_full_name>
    <investigator_title>Department of Pharmacology and Pharmacogenomics Research Center</investigator_title>
  </responsible_party>
  <keyword>CYP2C8</keyword>
  <keyword>genetic polymorphism</keyword>
  <keyword>rosiglitazone</keyword>
  <keyword>Korean</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

